← Eichor
Study identifier: NCT06883214 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application

Condition: Glioma  ·  Sponsor: Regina Elena Cancer Institute

PhaseN/A
Planned participants10
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.

This description comes directly from the study's public registry record.

Talk to the study team

Ana Belen Diaz, Doctor  ·  06-52662522  ·  anabelen.diaz@ifo.it

Always discuss trial participation with your own doctor first.

Locations (1)

"Regina Elena" National Cancer InstituteRome, Rome, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06883214